2025年4月9日-爬墙专用加速器
2025年4月9日-爬墙专用加速器
Luis
Supply Chain at Apellis
2025年4月9日-爬墙专用加速器
Learn More
2025年4月9日-爬墙专用加速器
2025年4月9日-爬墙专用加速器
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
2025年4月9日-爬墙专用加速器
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
w加速器官网
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
@ApellisPharma
2025年4月9日-爬墙专用加速器
FOR PATIENTS
2025年4月9日-爬墙专用加速器
for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.
2025年4月9日-爬墙专用加速器
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.
CLINICAL TRIALS2025年4月9日-爬墙专用加速器
so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike
We challenge conventional thinking and always question if there's a better way.
Join Us
Patricia
Quality Assurance at Apellis
This website is intended for residents of the U.S.